PTC Therapeutics director Michael Schmertzler sells $1.8m in shares
PTC Therapeutics director Michael Schmertzler sold approximately $1.8 million worth of company shares in late August. The transactions occurred between August 26 and August 27, 2026, with shares traded at prices ranging from $71.55 to $73.18 per share. Schmertzler, along with Section Six Partners, L.P., executed these sales through a pre-arranged Rule 10b5-1 trading plan. The company's stock currently trades at $70.09, having delivered a 42% return over the past year, despite a 8% decline year-to-date.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
